novartis

in Health care

Submit complete safety data: CDSCO panel tells Novartis on Remibrutinib

by April 23, 2023, 1:12 pm

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has recommended the drug maker Novartis to submit complete safety data of the ongoing study of Bruton’s tyrosine kinase inhibitor Remibrutinib till date for further review by the committee to allow an extension of the current study. Bruton’s tyrosine […] More
Newsletter

Want more stuff like this?

Get the best viral stories straight into your inbox!

Email address:

Don't worry, we don't spam
in Health care

Novartis bid to revive multiple sclerosis drug Gilenya patent rebuffed by US Supreme Court

by April 18, 2023, 6:36 am

Washington: The U.S. Supreme Court on Monday declined to hear Novartis Pharmaceuticals Corp’s bid to revive a key patent on its blockbuster multiple sclerosis drug Gilenya that was invalidated amid a legal dispute with China’s HEC Pharm Co Ltd. The justices turned away an appeal by Novartis of a lower court’s decision to cancel the patent, a […] More
in Health care

Cipla joins hands with Novartis Pharma AG to market diabetes drug Galvus in India

by April 10, 2023, 9:40 am

Mumbai: Pharma major, Cipla Limited, has announced that it has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) to manufacture and market Galvus and Galvus combination brands, used in the treatment of type 2 diabetes from 1st January 2026. The agreement is subject to satisfaction of certain conditions precedent, Cipla informed. “During the […] More
in Health care

Novartis halts UK trial of anticholesterol drug Leqvio

by March 24, 2023, 9:26 am

Novartis said on Wednesday that it had decided not to move forward with ORION-17, the UK-based primary prevention trial originally planned as part of its partnership with NHS England to investigate the potential of the anti-cholesterol drug Leqvio. “After careful evaluation, we have decided not to move forward with ORION-17,” a spokesperson said in an […] More
in Health care

Novartis gets CDSCO panel nod for Phase III CT of anticancer drug Ianalumab

by March 23, 2023, 4:24 pm

New Delhi: In a significant development, pharmaceutical major Novartis has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase III clinical trial of anticancer drug Ianalumab (VAY736). However, this approval is subject to the condition that the applicant submit safety data on […] More